Immunic Financial Statements From 2010 to 2021

IMUX -  USA Stock  

USD 8.47  0.04  0.47%

Immunic financial statements provide useful quarterly and yearly information to potential Immunic investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Immunic financial statements helps investors assess Immunic's valuation, profitability, and current liquidity needs.
We have found sixty-three available fundamental trends for Immunic, which can be analyzed and compared to other ratios and to its competitors. Make sure you confirm all of Immunic regular market performance against the performance between 2010 and 2021 to make sure the company can sustain itself down the road.
Working Capital is likely to rise to about 135.2 M in 2021, whereas Average Assets are likely to drop slightly above 104 M in 2021.

Immunic Financial Statements 

 
Refresh
Check Immunic financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immunic main balance sheet or income statement drivers, such as Operating Expenses of 47.3 M, Preferred Dividends Income Statement Impact of 8.7 M or Research and Development Expense of 36.2 M, as well as many exotic indicators such as Book Value per Share of 10.94, Current Ratio of 13.8 or Debt to Equity Ratio of 0.0615. Immunic financial statements analysis is a perfect complement when working with Immunic Valuation or Volatility modules. It can also supplement various Immunic Technical models. Please see the analysis of Immunic Correlation against competitors.

Immunic Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets181.1 M167.9 M71.5 M
Increasing
Slightly volatile
Cash and Equivalents137.5 M127.5 M55.5 M
Increasing
Slightly volatile
Investments12.5 M12.6 M13.8 M
Decreasing
Slightly volatile
Investments Current12.5 M12.6 M13.8 M
Decreasing
Slightly volatile
Property Plant and Equipment Net1.4 M1.1 M1.7 M
Decreasing
Stable
Trade and Non Trade PayablesM3.7 M1.7 M
Increasing
Slightly volatile
Goodwill and Intangible Assets29.5 M29.7 M32.4 M
Decreasing
Slightly volatile
Total Liabilities12.8 M9.1 M20 M
Decreasing
Slightly volatile
Shareholders Equity171.3 M158.8 M48.6 M
Increasing
Slightly volatile
Accumulated Other Comprehensive Income(4.2 M)(4.1 M)(819.5 K)
Decreasing
Slightly volatile
Current Assets105.9 M133.7 M58 M
Increasing
Slightly volatile
Assets Non Current36.8 M34.1 M10.3 M
Increasing
Slightly volatile
Current Liabilities8.2 M8.4 M5.9 M
Increasing
Slightly volatile
Liabilities Non Current696.9 K679 K13.8 M
Decreasing
Slightly volatile
Total Debt704.4 K679 K548.6 K
Increasing
Slightly volatile
Debt Non Current704.4 K679 K548.6 K
Increasing
Slightly volatile
Shareholders Equity USD171.3 M158.8 M48.6 M
Increasing
Slightly volatile
Cash and Equivalents USD137.5 M127.5 M55.5 M
Increasing
Slightly volatile
Total Debt USD704.4 K679 K548.6 K
Increasing
Slightly volatile

Immunic Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General and Administrative Expense11.2 M10.3 M9.1 M
Increasing
Slightly volatile
Research and Development Expense36.2 M38.6 M24.4 M
Increasing
Slightly volatile
Operating Expenses47.3 M49 M33.5 M
Increasing
Slightly volatile
Interest Expense(924)(900)102.5 K
Decreasing
Slightly volatile
Preferred Dividends Income Statement Impact8.7 M10.5 M6.9 M
Increasing
Slightly volatile
Weighted Average Shares16.9 M15.7 M3.7 M
Increasing
Slightly volatile
Weighted Average Shares Diluted16.9 M15.7 M3.7 M
Increasing
Slightly volatile

Immunic Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Cash Flow Business Acquisitions and Disposals9.4 M9.5 M10.4 M
Decreasing
Slightly volatile
Net Cash Flow Investment Acquisitions and Disposals17.4 M16.1 M7.5 M
Increasing
Slightly volatile
Net Cash Flow from Financing155.8 M144.4 M56.4 M
Increasing
Slightly volatile
Issuance Repayment of Debt Securities 5.7 M5.8 M6.3 M
Decreasing
Slightly volatile
Issuance Purchase of Equity Shares155.8 M144.4 M45.3 M
Increasing
Slightly volatile
Net Cash Flow from Investing(149.8 K)(146 K)(2.1 M)
Increasing
Slightly volatile
Effect of Exchange Rate Changes on Cash (84.2 K)(78 K)(138.8 K)
Decreasing
Slightly volatile
Net Cash Flow or Change in Cash and Cash Equivalents105.8 M98.1 M24.4 M
Increasing
Slightly volatile
Share Based Compensation3.4 M2.7 M3.1 M
Increasing
Slightly volatile
Depreciation Amortization and Accretion40 K39 K676.4 K
Decreasing
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Return on Average Equity(0.42)(0.391)0.0336
Decreasing
Slightly volatile
Return on Invested Capital42.8850.14821.3707
Increasing
Slightly volatile
Enterprise Value over EBITDA(4.52)(4.192)(6.3427)
Increasing
Slightly volatile
Enterprise Value over EBIT(4.32)(4.0)(6.3596)
Increasing
Slightly volatile
Price to Book Value2.321.9953.9849
Decreasing
Slightly volatile
Debt to Equity Ratio0.06150.057(1.0308)
Increasing
Slightly volatile
Current Ratio13.815.9289.9907
Increasing
Very volatile
Book Value per Share10.9410.137(422)
Increasing
Slightly volatile
Tangible Assets Book Value per Share8.848.612823
Decreasing
Slightly volatile

Immunic Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Capitalization272.5 M316.8 M367.4 M
Decreasing
Slightly volatile
Enterprise Value175.3 M184.3 M294.4 M
Decreasing
Slightly volatile
Invested Capital(301 K)(279 K)1.7 M
Decreasing
Slightly volatile
Average Equity89.1 M112.7 M35.1 M
Increasing
Slightly volatile
Average Assets104 M121 M63.4 M
Increasing
Slightly volatile
Invested Capital Average(947 K)(877.8 K)801.1 K
Decreasing
Slightly volatile
Tangible Asset Value107.6 M134.9 M59.8 M
Increasing
Slightly volatile
Working Capital135.2 M125.3 M55.2 M
Increasing
Slightly volatile

Immunic Fundamental Market Drivers

Short Percent Of Float4.11%
Forward Price Earnings-2.33
Shares Short Prior Month1.64M
Average Daily Volume Last 10 Day214.08k
Average Daily Volume In Three Month232.77k
Date Short Interest31st of August 2021
Fifty Day Average9.01
Two Hundred Day Average11.46

Immunic Upcoming Events

Upcoming Quarterly Report4th of November 2021
Next Earnings Report25th of February 2022
Next Fiscal Quarter End30th of September 2021
Next Fiscal Year End25th of February 2022
Last Quarter Report30th of June 2021
Last Earning Announcement30th of September 2020

About Immunic Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Immunic income statement, its balance sheet, and the statement of cash flows. Immunic investors use historical funamental indicators, such as Immunic's revenue or net income, to determine how well the company is positioned to perform in the future. Although Immunic investors may use each financial statement separately, they are all related. The changes in Immunic's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Immunic's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Immunic Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Immunic. Please read more on our technical analysis and fundamental analysis pages.
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. t and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 45 people.

Immunic Investors Sentiment

The influence of Immunic's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Immunic. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Current Sentiment - IMUX

Immunic Investor Sentiment

Macroaxis portfolio users are indifferent in their judgment towards investing in Immunic. What is your judgment towards investing in Immunic? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Immunic using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see the analysis of Immunic Correlation against competitors. Note that the Immunic information on this page should be used as a complementary analysis to other Immunic's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.

Complementary Tools for Immunic Stock analysis

When running Immunic price analysis, check to measure Immunic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunic is operating at the current time. Most of Immunic's value examination focuses on studying past and present price action to predict the probability of Immunic's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immunic's price. Additionally, you may evaluate how the addition of Immunic to your portfolios can decrease your overall portfolio volatility.
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
The market value of Immunic is measured differently than its book value, which is the value of Immunic that is recorded on the company's balance sheet. Investors also form their own opinion of Immunic's value that differs from its market value or its book value, called intrinsic value, which is Immunic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunic's market value can be influenced by many factors that don't directly affect Immunic underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunic's value and its price as these two are different measures arrived at by different means. Investors typically determine Immunic value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.